001     304578
005     20250916115007.0
024 7 _ |a 10.3390/ijms26178431
|2 doi
024 7 _ |a pmid:40943355
|2 pmid
024 7 _ |a pmc:PMC12428964
|2 pmc
024 7 _ |a 1422-0067
|2 ISSN
024 7 _ |a 1661-6596
|2 ISSN
037 _ _ |a DKFZ-2025-01901
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Paret, Claudia
|0 0000-0002-9094-1634
|b 0
245 _ _ |a Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.
260 _ _ |a Basel
|c 2025
|b Molecular Diversity Preservation International
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1757942194_16315
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:A411#
520 _ _ |a High-risk (HR) neuroblastoma (NBL) patients often receive standardized treatment despite wide variations in clinical outcomes, underscoring the need for improved stratification tools. A distinguishing feature of NBL is the patient-specific expression of gangliosides (GGs), particularly GD2, which may serve as biomarkers. We analyzed GG profiles in 18 patient-derived tumors and 11 NBL cell lines using thin-layer chromatography and mass spectrometry. Expression of 0-, a-, and b-series GGs was examined and correlated with clinical risk, outcome, and gene expression data. Low-risk (LR) tumors expressed higher levels of complex b-series GGs. In HR tumors, five GG profiles (A-E) were identified. Profile A featured complex b-series GGs; B showed GD2 dominance; C showed synthesis arrest at GM3 or GD3 due to low expression of the GM2/GD2 synthase, encoded by the B4GALNT1 gene; D included complex a- and b-series GGs; and E was marked by GM2 and GD1a prevalence. B4GALNT1 expression served as a prognostic marker. Relapsed tumors following anti-GD2 therapy typically exhibited reduced GD2 levels, except for one profile A tumor that displayed a ceramide anchor shorter than those found in LR tumors. Astonishingly, the ceramide anchor composition of GD2 itself appears to separate LR and HR NBL, hinting at a role of ceramide synthases in NBL biology. All cell lines expressed GM2, but exhibited very low levels of complex b-series GGs. Profile C was found only in cell lines of the mesenchymal subtype. These findings support further investigation of GG composition and associated enzyme expression as potential biomarkers for risk stratification and treatment response in NBL.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a B4GALNT1
|2 Other
650 _ 7 |a GD2
|2 Other
650 _ 7 |a ceramide
|2 Other
650 _ 7 |a dinutuximab
|2 Other
650 _ 7 |a gangliosides
|2 Other
650 _ 7 |a naxitamab
|2 Other
650 _ 7 |a neuroblastoma
|2 Other
700 1 _ |a Wingerter, Arthur
|0 0000-0002-9547-6532
|b 1
700 1 _ |a Seidmann, Larissa
|b 2
700 1 _ |a Ustjanzew, Arsenij
|0 0000-0002-1014-4521
|b 3
700 1 _ |a Sathyamurthy, Shobha
|0 P:(DE-He78)eed6fe97052c756d0687ec76e1482a48
|b 4
700 1 _ |a Ludwig, Jannis
|0 P:(DE-He78)cd764889416fbd07d52c2d6165a10de6
|b 5
|u dkfz
700 1 _ |a Schwickerath, Philipp
|0 P:(DE-He78)162b38d51ca6309406801d95f34d67c9
|b 6
|u dkfz
700 1 _ |a Brignole, Chiara
|0 0000-0002-2563-6991
|b 7
700 1 _ |a Pastorino, Fabio
|0 0000-0002-8312-808X
|b 8
700 1 _ |a Wagner, Saskia
|0 0009-0000-4840-6614
|b 9
700 1 _ |a El Malki, Khalifa
|b 10
700 1 _ |a Roth, Wilfried
|b 11
700 1 _ |a Sandhoff, Roger
|0 P:(DE-He78)a928ded2085c8911822370cad0b4a728
|b 12
|e Last author
|u dkfz
700 1 _ |a Faber, Jörg
|0 0000-0002-5432-8234
|b 13
773 _ _ |a 10.3390/ijms26178431
|g Vol. 26, no. 17, p. 8431 -
|0 PERI:(DE-600)2019364-6
|n 17
|p 8431
|t International journal of molecular sciences
|v 26
|y 2025
|x 1422-0067
909 C O |o oai:inrepo02.dkfz.de:304578
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 0000-0002-9094-1634
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)eed6fe97052c756d0687ec76e1482a48
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)cd764889416fbd07d52c2d6165a10de6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)162b38d51ca6309406801d95f34d67c9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)a928ded2085c8911822370cad0b4a728
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 0000-0002-5432-8234
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-21
920 2 _ |0 I:(DE-He78)A411-20160331
|k A411
|l Lipid-Pathobiochemie
|x 0
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK Koordinierungsstelle Frankfurt
|x 0
920 1 _ |0 I:(DE-He78)A411-20160331
|k A411
|l Lipid-Pathobiochemie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a I:(DE-He78)A411-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21